TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy

Loss of p53 promotes vascular endothelial growth factor (VEGF)-A up-regulation and the angiogenic potential of cancer cells. We investigated TP53 somatic mutations in 110 primary gastric adenocarcinomas of two retrospective metastatic series including 48 patients treated with second-line Ramucirumab...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Cancers (Basel)
Κύριοι συγγραφείς: Graziano, Francesco, Fischer, Nicholas W., Bagaloni, Irene, Di Bartolomeo, Maria, Lonardi, Sara, Vincenzi, Bruno, Perrone, Giuseppe, Fornaro, Lorenzo, Ongaro, Elena, Aprile, Giuseppe, Bisonni, Renato, Prisciandaro, Michele, Malkin, David, Gariépy, Jean, Fassan, Matteo, Loupakis, Fotios, Sarti, Donatella, Del Prete, Michela, Catalano, Vincenzo, Alessandroni, Paolo, Magnani, Mauro, Ruzzo, Annamaria
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: MDPI 2020
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7465166/
https://ncbi.nlm.nih.gov/pubmed/32722340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12082049
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια